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Abstract
Aims: With the aim to improve peptide receptor radionuclide therapy effects in patients with gastroenteropancreatic
neuroendocrine tumor (GEPNET) liver metastases we explored the effect of intra-arterial (IA) administration of
[111In-DTPA]octreotide (111In-DTPAOC) on tumor uptake in an animal model and in a patient study.
Methods: Preclinical study: After administering 111In-DTPAOC intra-venously (IV) or IA, biodistribution
studies were performed in rats with a hepatic somatostatin receptor subtype 2 (sst2)-positive tumor. Clinical
study: 3 patients with neuroendocrine liver metastases were injected twice with 111In-DTPAOC. The first
injection was given IV, and 2 weeks later, the second was injected IA (hepatic artery). Planar images of the
abdomen were made up to 72 hours after injection. Blood samples were taken and urine was collected.
Pharmacokinetic modeling was performed on the IV and IA data of the same patient. Based on this model,
additional 177Lu dosimetry calculations for IV and IA administrations were performed.
Results: The preclinical study showed a two-fold higher 111In-DTPAOC tumor uptake after IA administration
than after IV injection. Patient data showed a large variability in radioactivity increment in liver metastases after
IA administration compared with IV administration. Renal radioactivity was not significantly lower after IA
administration; 177Lu dosimetry simulations in 1 patient using a maximum kidney radiation dose of 23Gy
showed IA administration resulted in a mean increase in tumor radiation dose of 2.9-fold.
Conclusion: Preclinical and clinical data both indicate that IA administration of radiolabeled somatostatin
analogs via the hepatic artery can significantly increase radionuclide uptake in GEPNET, sst2-positive, liver
metastases up to 72 hours postinjection, although the effect of IA administration can differ between patients.
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Introduction
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are usually slow growing tumors that are often
metastasized at time of diagnosis. In these cases curative
treatment by surgery is most often not an option anymore.
Various chemotherapeutic agents like streptozotocin, doxo-
rubicin, 5-fluorouracil, chlorozotocin, etoposide, and cis-
platin have been and are still being used alone or in
combination for treatment of GEPNETs. Variable objective
response rates and considerable toxicity were encountered
though.1 Recent studies show encouraging results in terms of
tumor growth control by inhibition of growth factor receptors
like vascular endothelial growth factor receptor, platelet-
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derived growth factor receptor, and C-kit by sunitinib mal-
eate.2 In addition, inhibition of the mammalian target of
rapamycin signal transduction pathway in GEPNETs by
Everolimus (RAD001) most recently demonstrated a signif-
icantly improved progression-free survival of 11 months
compared with 4.6 months observed in the placebo-treated
patients.3 Unfortunately, the affect on overall survival has not
been shown yet. Despite these promising developments the
standard biotherapy treatment at present is by somatostatin
analogs like octreotide (short acting or long acting release).
Octreotide treatment mainly aims at prevention of carcinoid
syndrome and has been described to inhibit tumor growth to
some extent.4 Overexpression of the somatostatin 2 receptor
(sst2) on GEPNETs resulted in the 1980s in the development
of radiolabeled somatostatin analogs like [111In-DTPA]oc-
treotide (111In-DTPAOC) for visualization of sst2-expressing
NETs. In the past decade, several radiolabeled somatostatin
analogs have not only been applied for visualization of NETs
but also for peptide receptor radionuclide therapy (PRRT).
Initial PRRT studies were performed with high doses of
the Auger electrons and c-emitting 111In-DTPAOC5 and later
with the b- and c-emitting radiopeptide [177Lu-DOTA,
Tyr3]octreotate (177Lu-DOTATATE) and the b-emitting
[90Y-DOTA,Tyr3]octreotide (90Y-DOTATOC), both being
applied now for treatment of GEPNETs. 177Lu-DOTATATE
and 90Y-DOTATOC studies have shown very convincing
results with regard to tumor response, overall survival, and
quality of life.6,7 Few side effects have been reported. Dose
limiting organs due to radiotoxic effects are bone marrow8
and the kidneys, the organs of excretion in PRRT. Co-
infusion of amino acids reduces kidney uptake and the renal
radiation dose.9,10 The maximum administered activity is
usually 29.6GBq for 177Lu-DOTATATE and 22.2GBq/m2
for 90Y-DOTATOC. Complete responses are still rare though.
We hypothesized that a higher tumor uptake of the radio-
pharmaceutical would improve the currently suboptimal
tumor response.
Up to 75% of GEPNET patients have liver metastasis at
time of diagnosis.11 The aim of this study was to use intra-
arterial (IA) administration of the radioligand via the common
hepatic artery to increase tumor uptake of 111In-DTPAOC.
McStay et al. demonstrated IA PRRT with 90Y-lanreotide to
be safe and at least as effective as intravenous (IV) admin-
istration.12 Limouris et al. also showed encouraging results
with IA PRRT with 111In-DTPAOC, 90Y-DOTATOC, and/or
177Lu-DOTATATE.13,14 There was little proof of increased
radiolabeled somatostatin analogue tumor uptake, until a
2009 study by Beauregard et al. reported that 3 patients had
a 72% increased tumor to kidney ratio after IA 177Lu-
DOTATATE, in comparison with IV 177Lu-DOTATATE
PRRT. Intra-individually in 1 patient IV and IA administered
68Ga-DOTATATE was quantified by PET imaging at 30
minutes postinjection (pi), showing a five-fold increase in
tumor uptake after IA administration.15 Kratochwil et al.
showed IA administration resulted in a 1.4–7.8-fold (mean
3.75) higher tumor uptake of 68Ga-DOTATOC as quantified
by PET imaging at 40 minutes pi.16 The same group also
reported on the pharmacokinetics after IA and IV 20 minutes
infusion of 111In-DOTATOC intra-individual in patients with
GEPNETs. At the end of IA infusion tumor uptake was 3.5-
fold higher compared with IV. This tumor uptake showed a
decrease to a 2-fold ratio at 4 hours pi and a 1.3-fold ratio at
72 hours pi. Additionally, impressive objective responses
were reported after IA administration of 90Y- and/or 177Lu-
DOTATOC in 15 patients with GEPNET liver metastasis.16 In
our study, we explored the effect of IV versus IA administration
of 111In-DTPAOC on tumor uptake in an sst2-expressing liver
metastasis model in the rat and intra-individually in 3 GEPNET
patients with liver metastasis up to 72 hours pi. Based on the
longitudinal measurements with 111In-DTPAOC we performed
pharmacokinetic modeling and simulated 177Lu dosimetry on
tumor tissue and healthy organs. Here, we describe major dif-
ferences between 3 patients with regard to the ratio of tumor




For the animal experiments 111InCl3 was purchased from
Covidien (Petten, The Netherlands). DTPAOC (Octreoscan)
was obtained from Tyco Health Care (Petten, The Nether-
lands). Radiolabeling was performed according to previously
published procedures.17 The labeling efficiency exceeded
99%, as confirmed by thin-layer chromatography. The spe-
cific activity of 111In-DTPAOC was 3MBq/0.5lg peptide.
For the human study the commercially available Oc-
treoscan kit (111In-DTPAOC) was used in a specific activity
of 220MBq/10 lg peptide.
Liver metastasis model in the rat
The animal studies were in accordance with the Animal
Welfare Committee requirements of our institution and were
FIG. 1. Schematic representation of the surgical technique
used in rats to provide an intra-arterial (IA) route of adminis-
tration to the liver. Before injection of [111In-DTPA]octreotide
(111In-DTPAOC) the ligatures around the common and proper
hepatic artery were removed to restore normal blood flow to-
wards the liver. Color image available online at www.liebertpub
.com/cbr
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conducted following generally accepted guidelines. For the
experiments, male Lewis rats (Harlan, Horst, The Nether-
lands) bearing an intra-hepatical CA20948 tumor18 were
used (n = 6 per group, 2 groups). Mean bodyweight at the
time of tumor inoculation was 300 g. All surgical and in-
jection procedures were performed under isoflurane/O2 an-
esthesia and using a microsurgery microscope. During
surgery, animals were kept warm with a heating pad.
After laparotomy of the rat’s upper abdomen, the main
liver lobe was fixated between two swabs and 1.5 · 106
CA20948 tumor cells suspended in 100lL matrigel base-
ment membrane matrix (BD Biosciences, San Jose, CA)
were injected subcapsularly via a 27-gauge needle. The
abdomen was closed by absorbable sutures.
On day 14 after inoculation, laparotomy of the abdomen was
performed again by a 3.5 cm incision along the linea alba.
Silicon tubing (inner diameter 0.012 inch and outer diameter
0.025 inch) was placed in the gastroduodenal artery with the tip
just in front of the bifurcation of the common and proper he-
patic arteries. A sham laparotomy was performed on all animals
that received IV 111In-DTPAOC administration. A schematic
representation of the surgical technique used to provide an IA
route of administration to the liver is shown in Figure 1.
Before injection, the blood supply to the liver was re-
stored by removing the ligatures around the proper and
common hepatic arteries, necessary for placement of the
silicon tubing without major blood loss. One hundred fifty
microliters of 3MBq/0.5 lg 111In-DTPAOC was injected in
about 3 seconds. After injection the catheter was flushed
with saline and removed.
After euthanasia at 24 hours pi normal organs and tumors
were dissected and blood samples were taken. Organs and
tumors were weighed and radioactivity was measured with a
gamma counter (Wallac, 1480 Wizard 3"; PerkinElmer,
Turku, Finland). The uptake of radioactivity was expressed as
the percentage of injected activity per gram tissue (%IA/g).
MicroSPECT/CT imaging
One additional rat with a subcapsular CA20948 tumor in
the liver was imaged by microSPECT/CT imaging. Twenty-
four hours before scanning, the rat was injected IV with
30MBq/0.5lg 111In-DTPAOC. Scanning was performed with
a four-headed multi-pinhole NanoSPECT/CT camera (Bios-
can, Inc., Washington, DC). Nine pinhole-apertures with a
diameter of 2.5mm were used with 24 projections (1 minute
per projection). The 111In energy peaks were set at 171 and
245 keV. Guided by the CT topogram, the upper abdomen was
scanned for 60 seconds per projection. The whole procedure
was performed under Isoflurane/O2 anesthesia. SPECT scans
were reconstructed iteratively using InVivoScope software
version 1.32 (Bioscan, Inc.) with medium noise reduction, a
voxel size of 0.3mm3, and standard reconstruction settings.
Patient study
Three patients (age 32, 54, and 64 years) with metastatic
nonresectable pancreatic NETs were enrolled to receive two
injections of 111In-DTPAOC; one IV injection and one IA
injection with a 2 week-interval. From previous imaging it
was known that these patients had hepatic metastasis enabling
FIG. 2. (A) Intrahepatic
CA20948 tumor 10 days after in-
oculation. (B) 111In-DTPAOC up-
take in an intrahepatic CA20948
tumor visualized by micro-SPECT/
CT. Red arrow, intrahepatic CA
20948 tumor; green arrows,
kidneys. Color images available
online at www.liebertpub.com/cbr
FIG. 3. (A) Percentage injected
111In-DTPAOC activity per gram
tissue in tumor and several organs
after intravenous (IV) and IA ad-
ministration in CA20948 in-
trahepatic tumor bearing rats
(mean – standard deviation [SD])
*p < 0.05. (B) Dotplot of 111In-
DTPAOC uptake in the in-
trahepatic tumor after IV and IA
administration (mean, – SD),
p < 0.05.
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dosimetry measurements. All patients were on short acting
octreotide treatment (Sandostatin; Novartis, Basel, Switzer-
land), which was discontinued 24 hours prior to both injec-
tions. This 24 hours discontinuation was chosen because
before standard 177Lu-DOTATATE treatment the same pe-
riod of short acting octreotide treatment discontinuation is
used. The study was performed after written informed con-
sent from the patient to participate in this study, which was
approved by the Erasmus MC Medical Ethical Committee.
IA administration. IA administration was performed via
a catheter placed angiographically through Seldinger’s
technique via the femoral artery with the tip into the com-
mon hepatic artery. Immediately after this procedure the
patient was placed on the gamma camera bed in a supine
position. The 111In-DTPAOC was injected in about 10
seconds. The catheter was flushed with 10mL of 0.9% sa-
line. The same injection protocol was used for IV injected
111In-DTPAOC.
Imaging. All images were acquired with a dual-head
gamma camera Picker Prism 2000 XP (Philips, Eindhoven,
The Netherlands). The windows were centered over both
111In photon peaks (245 and 171 keV) with a width of 20%.
Parallel-hole, medium-energy general-purpose collimators
were used. After each injection method, the same scan
protocol was followed: dynamic imaging up to 30 minutes
pi with a field of view over the kidneys and liver for the
anterior and posterior projections (120 images, 15 seconds
per image). Upper abdomen anterior and posterior scans
were obtained at 1, 4, 24, 48, and 72 hours after injection.
The acquisition time for all scans was 20 minutes. The ac-
cumulated radioactivity in tumor and organs was quantified
by drawing regions of interest (ROIs) in Phillips odyssey LX
software.
Measurement of radioactivity in blood and urine. Blood
samples were drawn at 1 minute before and 2, 5, 10, 15, 20,
30 minutes and 1, 4, 24, 48, and 72 hours pi. Urine was
collected in four intervals: 0–1, 1–4, 4–24, and 24–48 hours
after pi. Radioactivity in blood samples was quantified using
a gamma counter (Cobra II Autogamma, Packard, a Canberra
Company). Radioactivity in urine samples was quantified
using a dose calibrator (VCD-404; Veenstra Instruments,
Joure, The Netherlands).
Pharmacokinetics and dosimetry. ROIs were drawn
manually on the anterior and posterior spot views of the
upper abdomen around tumor lesions, liver, spleen, and
kidneys. The background region was placed close to the
ROIs for background correction. The geometric mean value,
derived from the anterior and posterior scans, was taken and
corrected for attenuation and physical decay. The activity in
the syringe before injection minus the remaining activity in
the syringe after injection was defined as 100% of the in-
jected activity. A compartmental pharmacokinetic model
was used to fit double-exponential curves through the uptake
data. 177Lu dosimetry calculations were performed on tumor
FIG. 4. Patient 1; (A) planar posterior upper abdomen images showing higher 111In-DTPAOC uptake in neuroendocrine
liver metastasis at 1, 4, 24, 48, and 72 hours after IA and IV administration of 111In-DTPAOC. (B, C) Quantification of 111In
uptake in liver metastasis B and C (see first picture A) after IA and IV administration. IA administration resulted in both
liver metastases in a 2.4-fold increase of the area under the curve (AUC) compared with IV administration.
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and organs based on a supposed 23Gy radiation dose to the
kidneys after IV administration. Tumors were modeled as
spheres. Actual tumor diameters were measured by CT and
MRI. The organ and tumor residence times were used as
input into the Olinda/EXM radiation dosimetry code.19 The
bone marrow residence time was calculated from the plasma
activity concentration curve.8 The dosimetry output was not
corrected for the actual volumes of the organs. The dose to
the tumors was calculated by the spherical node option
within the Olinda/EXM code.
Statistics
Data were expressed as mean– standard deviation. Statistical
analysis was performed using the unpaired Student’s t-test.
Results
Liver metastasis model in the rat
Inoculation of CA20948 tumor cells from in vitro cultures,
mixed with matrigel, resulted in a palpable solid tumor (Fig.
2A) 10 days later. The tumor could clearly be visualized by
micro-SPECT scanning 24 hours pi of 111In-DTPAOC (Fig.
2B). Ex vivo biodistribution at 24 hours after injection revealed
the tumor uptake of 111In-DTPAOC administered via the
common hepatic artery to be twofold higher ( p< 0.05) than
the uptake after systemic (IV) administration (Fig. 3A, B).
Uptake in kidney, liver, stomach, duodenum, adrenals, blood,
and muscle did not significantly differ after both injection
methods. Surprisingly, after IA administration the radioactivity
in the pancreas was higher than after IV administration.
FIG. 5. Patient 2; (A) planar posterior upper abdomen images showing almost comparable 111In-DTPAOC uptake in
neuroendocrine liver metastasis at 1, 4, 24, 48, and 72 hours after IA and IV administration of 111In-DTPAOC. (B, C)
Quantification of 111In uptake in liver metastasis B and C (see first picture A) after IA and IV administration. IA admin-
istration resulted in liver metastasis B in a 1.06-fold increase of the AUC and in liver metastasis C in a 1.14-fold increase of
the AUC compared with IV administration. (D) Digital subtraction angiography illustrating the arterial blood supply and
positioning of the catheters tip during IA administration.
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Patient study
Low 111In-DTPAOC uptake (iso-intense compared to the
liver) was seen in the liver metastases of the first patient after
IV administration on all images made at 1, 4, 24, 48, and 72
hours pi. After IA administration in this patient clear visu-
alization of the liver metastases was obtained (Fig. 4A).
Quantification data of tumor uptake after IA administration
showed a 2.4-fold higher 111In-DTPAOC uptake (Fig. 4B, C)
in these liver metastases in comparison with that after IV
administration. Kidney uptake and urine radioactivity was not
significantly different after either route of administration.
Strikingly, in the second patient IA administration did not
result in significantly higher 111In-DTPAOC uptake in the
liver metastases. Quantification showed a 1.06- and 1.14-
fold increase of 111In-DTPAOC uptake after IA versus IV
FIG. 6. Patient 3; (A) planar anterior upper abdomen images showing 111In localization, 1, 4, 24, 48, and 72 hours after IA
and IV administration of 111In-DTPAOC. Notice the higher uptake after IA administration in comparison with IV ad-
ministration in hotspot 4 (2.3-fold increase of the AUC), which is not seen for hotspot 8. An additional image taken during
IA injection is shown. Notice only half the liver is receiving IA administration resulting in 111In-DTPAOC uptake com-
parable to systemic administration in the metastasis located in segment 5 of the liver (hotspot 8). (B) Regions of interest
(ROI) as used for calculating accumulated activity in tumors and organs. (C) Simplified compartmental model as used in the
SAAM II software. Organs and tumors were modeled as two compartmental. (D, E) Post IA (D) and IV (E) administration
data of patient 3 fitted in a pharmacokinetic model. (F) Plasma values and fits after IA and IV administration. Notice the
only difference in plasma values between IA and IV administration is only in the early time point (2 minutes postinjection).
(G) 177Lu tumor dosimetry after IV and IA administration. Radiation dose on all liver metastasis in the right part of the liver
(ROI 1–7) would be significantly increased by IA administration while the dose on the liver metastasis in the left part of the
liver (ROI 8) would not be significantly higher or lower compared with IV administration. (H) 177Lu organ dosimetry after
IV and IA administration.
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administration for metastasis B and C (Fig. 5A), respec-
tively. When compared with the first patient, the tumor
uptake was exceptionally high in patient 2. At 4 hours pi
after IV and IA administration around 30% of the injected
activity was located in the very large liver metastasis B (Fig.
5A), whereas for the first patient the maximum uptake was
only 0.5% of the injected activity in liver metastasis (Fig.
4A, metastasis B). So, tumor uptake in the second patient
was already exceptionally high after IV administration.
In a third patient three liver metastases were clearly vi-
sualized at 1, 4, 24, 48, and 72 hours post IV administration.
The equivalent scans after IA administration revealed sev-
eral additional liver metastatic lesions (Fig. 6A), whereas
the lesions that were visible on the IV scan showed higher
uptake after IA injection. Surprisingly, one metastatic nod-
ule (hotspot 8, Fig. 6A) also shown on the scan after IV
injection and located in liver segment 5 did not show an
increased 111In-DTPAOC uptake after IA administration.
Analysis of the dynamic scans made during the injection
phase, showed that the tip of the catheter in this patient was
not situated in the common hepatic artery, but in the right
hepatic artery (Fig. 6A, picture in the right upper corner). As
a result, 111In-DTPAOC was administered IA to the right
part of the liver, whereas the left part received the 111In-
DTPAOC after first pass through the body via systemic
administration.
Urine sample data, blood sample data, and region of interest
(tumors and kidneys, Fig. 6B) quantification data of this pa-
tient were fitted in a compartmental pharmacokinetic model
(Fig. 6C) for IA and IV administration in Figure 6D and E,
respectively. Quantification of 111In-DTPAOC uptake in liver
metastasis 4 (in the right part of the liver) over 72 hours
showed a mean 2.3-fold increase after IA versus IV admin-
istration (Fig. 6D, E). 111In-DTPAOC uptake in the metastasis
(hotspot 8) located in the left part of the liver showed to be
comparable after IA and IV administration. 111In-DTPAOC
kidney uptake was 13% lower after IA administration com-
pared with IV administration. The percentage injected activity
in plasma only differed significantly between IA and IV ad-
ministration at 2 minutes pi. Five minutes pi, IA and IV
plasma values were almost comparable (Fig. 6F).
Based on the compartmental pharmacokinetic model 177Lu
dosimetry calculations were performed (Fig. 6G) for all liver
metastasis after IA and IV administration assuming similar
pharmacokinetics for 111In-DTPAOC and 177Lu-DOTA-
TATE. Radiation dose with 177Lu-DOTATATE PRRT was
calculated for all metastases based on a radiation dose to the
kidneys of 23Gy after IA and IV administration. These cal-
culations showed for all metastases located in the right part of
the liver an increase of the radiation dose by a factor 1.9–4.5
after IA administration. The calculated radiation dose for
hotspot 8 in Figure 6A was not significantly different after IA
FIG. 6. (Continued)
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or IV administration. The estimated radiation dose to several
organs is shown in Figure 6H after an injected activity leading
to a renal radiation dose of 23Gy. Please note the relative
large (30%) renal radiation dose reduction after IA adminis-
tration. These calculations are performed on the data collected
from only 1 patient and definitely have no statistical signifi-
cance in predicting the results of IA administration in a group
of GEPNET patients.
As biodistribution study in rats showed increase of 111In-
DTPAOC in the pancreas after IA administration we looked
for pancreas uptake on the patient scans. But none of the scans
showed 111In-DTPAOC uptake in the pancreas. Therefore, a
possible increase of uptake in the pancreas after IA adminis-
tration via the hepatic artery could not be shown.
Discussion
Both the preclinical and clinical studies indicated that IA
hepatic administration of 111In-DTPAOC can result in a
significantly increased 111In-DTPAOC tumor uptake com-
pared with that after IV administration. This increased uptake
in the hepatic NET metastases will, when applying a thera-
peutic radiolabeled analogue such as 177Lu-DOTATATE
or 90Y-DOTATOC, result in a higher tumor absorbed radia-
tion dose.
In the animal study IA administration resulted in a dou-
bling of the 111In-DTPAOC uptake in both tumor and pan-
creas. This unexpected increase in pancreas (a sst2-positive
organ in the rat) uptake is most likely explained by backflow
of 111In-DTPAOC via the common hepatic artery and coe-
liac trunk into the aorta during injection.
In patient 2, IA administration did not result in signifi-
cantly higher tumor uptake. The large tumor volume in
combination with the high tumor sst2 expression (grade 4)
and the limited amount of peptide, only 10lg DTPAOC was
used, could have played a role here. Interesting is the fact
that in patient 2 within the time frame of 1–4 hours pi after
IA administration the uptake in the liver metastases was still
increasing while in both other patients the slope of the curve
was already declining at 1 hours pi. We cannot fully explain
this phenomenon right now, but we assume all receptors in
the liver metastases in patient 1 and 3 to be saturated after
IA administration, whereas in patient 2 binding of 111In-
DTPAOC was still possible at relatively low 111In-DTPAOC
plasma concentrations at later time points.
In patient 3, IA administration resulted in a 2.3-fold in-
crease in 111In-DTPAOC uptake in the metastasis located in
the right part of the liver. The fact that the one metastasis
located in the left part of the liver showed to have equal
uptake as measured after systemic administration suggests
that 111In-DTPAOC uptake in tumor lesions outside the liver
compartment, which was supplied by the IA-route, was
apparently not affected by the IA administration route. The
111In-DTPAOC plasma values showed significant difference
between IA and IV administration at 2 minutes pi (Fig. 6F)
and were almost equal at 5 minutes pi. Apparently, there
was sufficient radiopharmaceutical left to enter the systemic
circulation and reach other tumors. Therefore, an unsus-
pected metastasis outside the liver (if this patient had one)
would probably also have taken up the same amount of
111In-DTPAOC after IA administration as after IV admin-
istration. Certainly, this assumption can only be made in this
patient. Probably a higher hepatic tumor mass and/or sst2
density could even result in a lower uptake in extra hepatic
tumor lesions after IA administration compared with IV ad-
ministration. Despite kidney uptake and excretion was min-
imally decreased by IA administration, 177Lu dosimetry
calculations in patient 3 showed a 30% dose reduction to the
kidneys by IA administration. This reduced kidney and higher
intrahepatic tumor radiation dose resulted in a significant
increase of the therapeutic index. IA 177Lu-DOTATATE
PRRT would administer a 1.9–4.5 times higher estimated
tumor radiation dose when the kidney radiation dose would
be 23Gy. The radiation dose to the bone marrow did not
show a significant increase after IA administration. For these
calculations we assumed the pharmacokinetics for 111In-
DTPAOC and 177Lu-DOTATATE to be equal, but the fact
that 177Lu-DOTATATE has a four-fold higher affinity for the
sst2 and also shows some affinity for the sst5 indicates that our
dosimetry calculations are a rough estimation.
In the studies described here, the procedure differed from
the routine PRRT treatment with 177Lu-DOTATATE in our
institution. PRRT with 177Lu-DOTATATE is administered
in a 30 minutes infusion whereas in the current study 111In-
DTPAOC was injected as a bolus in 10 seconds. Second, the
amount of peptide used in a PRRT setting is 20 times the
amount of peptide we used in this study (200lg DOTA-
TATE versus 10lg DTPAOC). In addition, DTPAOC has a
four-fold lower affinity for the sst2 compared DOTATATE.
In our study, DTPAOC and not DOTATATE was used
because the scans were included in the standard clinical
workup for PRRT and not for research purposes only. Future
experiments with DOTATATE as ligand using a therapeutic
peptide dose and injection protocol will be performed to
show the additional effect of locoregional administration in
a therapeutic setting. In 2008 Limouris et al. showed a
relatively high tumor response rate after IA PRRT with
111In-DTPAOC in patients with GEPNET liver metastasis.13
This relatively high tumor response could be (partially)
caused by an increased 111In uptake after the IA adminis-
tration. Recently, Kratochwil et al. showed a mean 3.75-fold
increase of 68Ga-DOTATOC uptake at 40 minutes pi after
selective IA administration in GEPNETs.16 Considering our
observations at later time points obtained with 111In-DTPAOC
we feel this mean increase of 3.75-fold cannot be translated to
the tumor radiation dose. At 1 hours pi IA administration the
slope in the curve showing the % injected activity present in
the liver metastasis is still quite steep (Fig. 4B, C). Probably
a measurement at 24 hours pi, after the curve has a more
stable slope, would be more predictive in estimating the
increase in tumor uptake after IA administration. In this
study, we demonstrated that IA administration resulted in
the same (1 patient) or an increased 111In-DTPAOC uptake
in NET liver metastasis up to 2.4-fold compared with IV
administration over a period of 72 hours. The increase in
uptake after IA administration is probably depending on sst2
density, tumor load, and tumor perfusion. We therefore
conclude that locoregional IA administration should be
considered as the optimal route of administration in patients
in which the GEPNET tumor load is mainly localized in the
liver. Though, an increase in radionuclide tumor uptake after
IA administration in comparison to IV administration is not
guaranteed, as in one of our patients tumor uptake was high,
but similar after IV and IA administration. If IA PRRT will
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be applied, the positioning of the catheter should be well
planned using contrast enhanced CT for imaging of possible
hepatic arterial vasculature abnormalities.
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